A89.F Adocia SA

Healthcare Biotechnology Frankfurt Exchange
4.35 EUR
Close of Nov 12, 2026
2.03 8.99
Market cap
EUR 95.4M
P/E
-
P/B
28.18x
ROE
-1,112.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is A89.F undervalued?

Graham number

The Graham number of Adocia SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Adocia SA fundamental analysis

No fundamental analysis for Adocia SA yet.

Adocia SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Adocia SA

Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. The company's proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone GLP-1 Amylin, a combination of acting insulin glargine and rapid-acting insulin lispro, as well a…

Full company profile